The rise of testicular germ cell tumours

The search for causes, risk factors and novel therapeutic targets

Skye C. McIver, Shaun D. Roman, Brett Nixon, Kate L. Loveland, Eileen A. McLaughlin

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Since the beginning of the 20th century there has been a decline in the reproductive vitality of men within the Western world. The declining sperm quantity and quality has been associated with increased overt disorders of sexual development including hypospadias, undescended testes and type II testicular germ cell tumours (TGCTs). The increase in TGCTs cannot be accounted for by genetic changes in the population. Therefore exposure to environmental toxicants appears to be a major contributor to the aetiology of TGCTs and men with a genetic predisposition are particularly vulnerable. In particular, Type II TGCTs have been identified to arise from a precursor lesion Carcinoma in situ (CIS), identified as a dysfunctional gonocyte; however, the exact triggers for CIS development are currently unknown. Therefore the transition from gonocytes into spermatogonia is key to those studying TGCTs. Recently we have identified seven miRNA molecules (including members of the miR-290 family and miR-136, 463* and 743a) to be significantly changed over this transition period. These miRNA molecules are predicted to have targets within the CXCR4, PTEN, DHH, RAC and PDGF pathways, all of which have important roles in germ cell migration, proliferation and homing to the spermatogonial stem cell niche. Given the plethora of potential targets affected by each miRNA molecule, subtle changes in miRNA expression could have significant consequences e.g. tumourigenesis. The role of non-traditional oncogenes and tumour suppressors such as miRNA in TGCT is highlighted by the fact that the majority of these tumours express wild type p53, a pivotal tumour suppressor usually inactivated in cancer. While treatment of TGCTs is highly successful, the impact of these treatments on fertility means that identification of exact triggers, earlier diagnosis and alternate treatments are essential. This review examines the genetic factors and possible triggers of type II TGCT to highlight target areas for potential new treatments.

Original languageEnglish
Pages (from-to)1-11
Number of pages11
JournalF1000Research
Volume2
DOIs
Publication statusPublished - 19 Feb 2013
Externally publishedYes

Fingerprint

Tumors
Cells
MicroRNAs
Carcinoma in Situ
Therapeutics
Neoplasms
Stem Cell Niche
Molecules
Disorders of Sex Development
Hypospadias
Spermatogonia
Western World
Cryptorchidism
Testicular Germ Cell Tumor
Environmental Exposure
Genetic Predisposition to Disease
Oncogenes
Germ Cells
Cell Movement
Fertility

Cite this

McIver, Skye C. ; Roman, Shaun D. ; Nixon, Brett ; Loveland, Kate L. ; McLaughlin, Eileen A. / The rise of testicular germ cell tumours : The search for causes, risk factors and novel therapeutic targets. In: F1000Research. 2013 ; Vol. 2. pp. 1-11.
@article{8989cb11ff50415d965b9460fc07a90a,
title = "The rise of testicular germ cell tumours: The search for causes, risk factors and novel therapeutic targets",
abstract = "Since the beginning of the 20th century there has been a decline in the reproductive vitality of men within the Western world. The declining sperm quantity and quality has been associated with increased overt disorders of sexual development including hypospadias, undescended testes and type II testicular germ cell tumours (TGCTs). The increase in TGCTs cannot be accounted for by genetic changes in the population. Therefore exposure to environmental toxicants appears to be a major contributor to the aetiology of TGCTs and men with a genetic predisposition are particularly vulnerable. In particular, Type II TGCTs have been identified to arise from a precursor lesion Carcinoma in situ (CIS), identified as a dysfunctional gonocyte; however, the exact triggers for CIS development are currently unknown. Therefore the transition from gonocytes into spermatogonia is key to those studying TGCTs. Recently we have identified seven miRNA molecules (including members of the miR-290 family and miR-136, 463* and 743a) to be significantly changed over this transition period. These miRNA molecules are predicted to have targets within the CXCR4, PTEN, DHH, RAC and PDGF pathways, all of which have important roles in germ cell migration, proliferation and homing to the spermatogonial stem cell niche. Given the plethora of potential targets affected by each miRNA molecule, subtle changes in miRNA expression could have significant consequences e.g. tumourigenesis. The role of non-traditional oncogenes and tumour suppressors such as miRNA in TGCT is highlighted by the fact that the majority of these tumours express wild type p53, a pivotal tumour suppressor usually inactivated in cancer. While treatment of TGCTs is highly successful, the impact of these treatments on fertility means that identification of exact triggers, earlier diagnosis and alternate treatments are essential. This review examines the genetic factors and possible triggers of type II TGCT to highlight target areas for potential new treatments.",
keywords = "testicular germ cell tumours, seminoma, nonseminoma, primordial germ cell, differentiation, CIS",
author = "McIver, {Skye C.} and Roman, {Shaun D.} and Brett Nixon and Loveland, {Kate L.} and McLaughlin, {Eileen A.}",
year = "2013",
month = "2",
day = "19",
doi = "10.12688/f1000research.2-55.v1",
language = "English",
volume = "2",
pages = "1--11",
journal = "F1000Research",
issn = "2046-1402",
publisher = "F1000 Research Ltd.",

}

The rise of testicular germ cell tumours : The search for causes, risk factors and novel therapeutic targets. / McIver, Skye C.; Roman, Shaun D.; Nixon, Brett; Loveland, Kate L.; McLaughlin, Eileen A.

In: F1000Research, Vol. 2, 19.02.2013, p. 1-11.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The rise of testicular germ cell tumours

T2 - The search for causes, risk factors and novel therapeutic targets

AU - McIver, Skye C.

AU - Roman, Shaun D.

AU - Nixon, Brett

AU - Loveland, Kate L.

AU - McLaughlin, Eileen A.

PY - 2013/2/19

Y1 - 2013/2/19

N2 - Since the beginning of the 20th century there has been a decline in the reproductive vitality of men within the Western world. The declining sperm quantity and quality has been associated with increased overt disorders of sexual development including hypospadias, undescended testes and type II testicular germ cell tumours (TGCTs). The increase in TGCTs cannot be accounted for by genetic changes in the population. Therefore exposure to environmental toxicants appears to be a major contributor to the aetiology of TGCTs and men with a genetic predisposition are particularly vulnerable. In particular, Type II TGCTs have been identified to arise from a precursor lesion Carcinoma in situ (CIS), identified as a dysfunctional gonocyte; however, the exact triggers for CIS development are currently unknown. Therefore the transition from gonocytes into spermatogonia is key to those studying TGCTs. Recently we have identified seven miRNA molecules (including members of the miR-290 family and miR-136, 463* and 743a) to be significantly changed over this transition period. These miRNA molecules are predicted to have targets within the CXCR4, PTEN, DHH, RAC and PDGF pathways, all of which have important roles in germ cell migration, proliferation and homing to the spermatogonial stem cell niche. Given the plethora of potential targets affected by each miRNA molecule, subtle changes in miRNA expression could have significant consequences e.g. tumourigenesis. The role of non-traditional oncogenes and tumour suppressors such as miRNA in TGCT is highlighted by the fact that the majority of these tumours express wild type p53, a pivotal tumour suppressor usually inactivated in cancer. While treatment of TGCTs is highly successful, the impact of these treatments on fertility means that identification of exact triggers, earlier diagnosis and alternate treatments are essential. This review examines the genetic factors and possible triggers of type II TGCT to highlight target areas for potential new treatments.

AB - Since the beginning of the 20th century there has been a decline in the reproductive vitality of men within the Western world. The declining sperm quantity and quality has been associated with increased overt disorders of sexual development including hypospadias, undescended testes and type II testicular germ cell tumours (TGCTs). The increase in TGCTs cannot be accounted for by genetic changes in the population. Therefore exposure to environmental toxicants appears to be a major contributor to the aetiology of TGCTs and men with a genetic predisposition are particularly vulnerable. In particular, Type II TGCTs have been identified to arise from a precursor lesion Carcinoma in situ (CIS), identified as a dysfunctional gonocyte; however, the exact triggers for CIS development are currently unknown. Therefore the transition from gonocytes into spermatogonia is key to those studying TGCTs. Recently we have identified seven miRNA molecules (including members of the miR-290 family and miR-136, 463* and 743a) to be significantly changed over this transition period. These miRNA molecules are predicted to have targets within the CXCR4, PTEN, DHH, RAC and PDGF pathways, all of which have important roles in germ cell migration, proliferation and homing to the spermatogonial stem cell niche. Given the plethora of potential targets affected by each miRNA molecule, subtle changes in miRNA expression could have significant consequences e.g. tumourigenesis. The role of non-traditional oncogenes and tumour suppressors such as miRNA in TGCT is highlighted by the fact that the majority of these tumours express wild type p53, a pivotal tumour suppressor usually inactivated in cancer. While treatment of TGCTs is highly successful, the impact of these treatments on fertility means that identification of exact triggers, earlier diagnosis and alternate treatments are essential. This review examines the genetic factors and possible triggers of type II TGCT to highlight target areas for potential new treatments.

KW - testicular germ cell tumours

KW - seminoma

KW - nonseminoma

KW - primordial germ cell

KW - differentiation

KW - CIS

UR - http://www.scopus.com/inward/record.url?scp=84914814921&partnerID=8YFLogxK

U2 - 10.12688/f1000research.2-55.v1

DO - 10.12688/f1000research.2-55.v1

M3 - Article

VL - 2

SP - 1

EP - 11

JO - F1000Research

JF - F1000Research

SN - 2046-1402

ER -